Ocugen Inc. Common Stock (OCGN)
Stock · NASDAQ · Health Care
$0.7998as of 10/16/2026
Price chart
Active signals
OCGN Signal Track Record
How signals performed across all stocks →What OCGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -1.1% | 44% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 22 | -5.8% | 27% | October 9, 2026 |
| Bollinger Band Breakout | 19 | -0.9% | 47% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +0.2% | 57% | June 30, 2026 |
| Any 20-session window (baseline) | -4.4% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the tre…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 116
- Website
- ocugen.com/
Fundamentals
- 1-day range
- $0.79$0.85
- Market cap
- $420.50M
- P/E (trailing)
- —
- P/E (forward)
- -3.21
- EPS (trailing)
- $-0.20
- Dividend yield
- —
- Beta
- 1.91
- Avg. volume
- 6.17M
- Dividend pay date
- September 30, 2019
How Ocugen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Ocugen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- CABACabaletta Bio Inc. Common Stock$1.41▼ 9.03%Market cap $450.03MP/E —$1.51$4.23
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| CABA Cabaletta Bio Inc. Common Stock | $450.03M | — | $1.41 | ▼ 9.03% | $1.51$4.23 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Regionbenzinga · 10/14/2026
- Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European AffiliateYahoo · 10/6/2026
- Transcript: Ocugen Q2 2026 Earnings Conference CallBenzinga · 10/6/2026
- Ocugen to Participate in Upcoming Scientific ConferencesYahoo · 9/30/2026
- Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsightYahoo · 9/29/2026
- Ocugen to Participate in Upcoming October Investor and Industry ConferencesYahoo · 9/29/2026
- Sector Update: Healthcare Stocks Edge Higher in Afternoon TradingYahoo · 9/25/2026
- Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 DaysYahoo · 9/25/2026
- Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis PigmentosaYahoo · 9/25/2026
Insider Activity
Insider Actions →- Shankar Musunuri · September 9, 2026 · Sale57.3K @ $1.12
- Shankar Musunuri · September 9, 2026 · Sale468.7K @ $1.12
- Treerita Essalima Johnson-Greene · June 15, 2026 · Buy21.0K @ $1.23
- Kompella Uday · June 11, 2026 · Grant170.1K
- Chandrasekhar Satishchandran · June 11, 2026 · Grant170.1K
- Kirsten Castillo · June 11, 2026 · Grant170.1K
- Junge Zhang · June 11, 2026 · Grant170.1K
- Coleman Blaise · June 11, 2026 · Grant170.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 110.69M
- Total value held
- $198.39M
- Institutional holders
- 132
- Unknown13.93M
- Unknown13.80M
- Unknown9.67M
- Unknown8.05M
- Unknown7.30M
- Unknown7.28M
- Unknown6.67M
- Unknown4.23M
- Unknown3.96M
- Unknown3.77M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Ocugen Secures Bahamas Approval for Gene Therapy OCU400
Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.
Ocugen Secures Bahamas Approval for Gene Therapy OCU400. Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.